Chimeric anti-CD25 monoclonal antibody for treating acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation / 中华内科杂志
Chinese Journal of Internal Medicine
;
(12): 923-925, 2008.
Artigo
em Chinês
| WPRIM
| ID: wpr-397905
ABSTRACT
Objective To investigate the efficacy of chimeric anti-CD2 monoclonal antibody (basiliximab) on acute graft-versus-host disease (GVHD) in patients following aliogeneic hematopoietic stem cell transplantation. Methods Thirty-six patients who were suffered from acute GVHD from March 2005 to July 2007 were studied. All of them were treated with steroid first and got no response, then began basiliximab therapy. Results Thirty of 36 patients showed response to basiliximab therapy including 25 complete responses and 5 partial responses. The efficacy was associated with the degree of GVHD and the source of donor. Conclusion Patients suffered from steroid-resistant acute GVHD can be successfully treated with basiliximab.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Idioma:
Chinês
Revista:
Chinese Journal of Internal Medicine
Ano de publicação:
2008
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS